This paper presents daily, monthly and yearly variations of PAH mass concentrations measured in PM(10) particle fraction, collected at one measuring site in Zagreb air between 2001 and 2004, and seasonal differences in PAH mass concentrations in PM(10) samples collected from 21 March 2003 to 20 March 2004. Twenty-four hour samples were taken in the northern residential part of Zagreb using a low-volume (50 m(3)) sampler and glass or quartz filters. The analysis was performed using a high-performance liquid chromatograph (HPLC) and fluorescence detector with changeable excitation and emission wavelength. The annual average mass concentrations over the four-year measuring period for BaP ranged from 1.17 ng/m(3) in 2004 to 1.87 ng/m(3) in 2003 and were below the limit value (2 ng/m(3)) set by the Ordinance on Recommended and Limit Air Quality Values in Croatia. The highest concentrations of all PAHs measured in PM(10) samples collected from 21 March 2003 to 20 March 2004 were found in the winter and the lowest in the summer. Winter average of BaP was 2.94 ng/m(3) and summer average 0.12 ng/m(3). Autumn average was 2.76 ng/m(3) and was very similar to winter concentrations. Spring average of 0.58 ng/m(3) was higher than the summer average (0.12 ng/m(3)). Mass concentrations of all measured PAHs were much higher in the autumn than in the spring. Although annual averages for BaP did not exceed the limit value, autumn and winter BaP mass concentrations did, which calls for measures for reducing PAH emissions in the autumn and winter.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.envint.2007.12.022 | DOI Listing |
J Clin Pharmacol
January 2025
Department of Pharmacy, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Albuvirtide (ABT) is a novel long-acting fusion inhibitor for human immunodeficiency virus type 1 (HIV-1), and may be co-administered with rifampicin (RIF) in patients concurrent with tubercle bacillus and HIV-1. This study was conducted to investigate the pharmacokinetic effect of co-administration of the two drugs. In the study, 24 healthy volunteers were randomized to receive ABT alone or with RIF.
View Article and Find Full Text PDFClin Pharmacol Drug Dev
January 2025
Taiho Pharmaceutical Co., Ltd., Tokyo, Japan.
Pizuglanstat is a novel hematopoietic prostaglandin D synthase inhibitor and investigational treatment for Duchenne muscular dystrophy. This Phase 1 mass balance study aimed to characterize the absorption, metabolism, and excretion of carbon-14 (C)-labeled pizuglanstat in healthy adults (ClinicalTrials.gov, NCT04825431).
View Article and Find Full Text PDFFront Pharmacol
January 2025
School of Pharmacy, Jiangsu University, Zhenjiang, China.
Introduction: The L. (PVL) and Hand.-Mazz.
View Article and Find Full Text PDFFront Pharmacol
January 2025
Department of Anaesthesiology and Intensive Care Medicine, Faculty of General Medicine, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Târgu Mureș, Romania.
Knowledge of drug pharmacokinetics and tissue distribution is precious for ensuring patient safety and optimizing treatments. The varied use of local anesthetics, as well as the fact that anesthetics can sometimes have low therapeutic indices and numerous adverse drug reactions, makes any novel pharmacokinetics information valuable. The present manuscript describes a pharmacokinetic study of ropivacaine carried out after plane block anesthesia on an animal model, using high sensitivity, accurate, and precise LC-MS/MS bioanalysis.
View Article and Find Full Text PDFFront Neurol
January 2025
School of Public Health, Shanxi Medical University, Taiyuan, China.
Background: Cognitive impairment (CI) is a condition in which an individual experiences noticeable impairment in thinking abilities. Long-term exposure to aluminum (Al) can cause CI. This study aimed to determine the relationship between CI and MRI-related changes in postroom workers exposed to Al.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!